# ARASEC (NCT05059236)

> A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05059236
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Bayer
- Conditions: Metastatic Hormone-sensitive Prostate Cancer
- Interventions: Darolutamide (BAY1841788, Nubeqa); ADT
- Enrollment: 223
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- YouTube: 4
- Podcasts: 4
- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=arasec-nct05059236

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05059236", "email": "<work email>"}; the inbox owner confirms by the emailed link.